Brentuximab vedotin with cyclophosphamide, prednisone and doxorubicin for treating peripheral Tcell lymphoma

Brentuximab vedotin in combination with cyclophosphamide, prednisone and doxorubicin is in clinical development for the treatment of peripheral T-cell lymphoma (PTCL). Peripheral T-cell lymphomas (PTCLs) are a group of rare blood cancers. They develop in T-cells and affect the lymphatic system. PTCLs happen when the T-cells mutate and become cancerous cells that multiply uncontrollably. PTCL is a long-term debilitating and life-threatening condition, because in most cases the disease does not respond well to therapy, usually comes back within one year, and is associated with early death.